CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
DDReg Pharma›
News
DDReg Pharma

DDReg Pharma

DDReg Pharma provides regulatory consulting and pharmacovigilance services to pharmaceutical and biopharma companies through in-house reg-tech platforms.

Gurugram, Haryana, IN🇮🇳
Founded
2009
Loading
Overview
Compare
Employees
News
Library

Latest News About DDReg Pharma

Excellence in Pharma Service Company of the Year | FE Pharma

DDReg Pharma

Excellence in Pharma Service Company of the Year | FE Pharma

Honoured at FE Pharma Summit & Awards 2026, DDReg Pharma continues to set benchmarks in regulatory affairs and pharma services globally

Apr 3, 2026

DDReg Honored at ET Health Conclave 2025 for Excellence in Life Sciences Services

DDReg Pharma

DDReg Honored at ET Health Conclave 2025 for Excellence in Life Sciences Services

We're happy to share that DDReg pharma Honored at ET Health Conclave 2025 in life sciences industry. For More, Read our post.

Aug 4, 2025

DDReg Celebrates 16 Years of Enabling Access to Global Healthcare

Issuewire

DDReg Celebrates 16 Years of Enabling Access to Global Healthcare

DDReg Celebrates 16 Years of Enabling Access to Global Healthcare - IssueWire

Jul 4, 2025

Quantiphi, DDReg Partner to Transform Regulatory Reporting in Life Sciences Through AI

ThePrint

Quantiphi, DDReg Partner to Transform Regulatory Reporting in Life Sciences Through AI

NewsVoir Gurgaon (Haryana) [India], November 6: Quantiphi, a global AI-first digital engineering company and DDReg, a global leader in...

Nov 6, 2024

Managing Director of DDReg chosen as finalist for CPhI Pharma Awards 2024

DDReg Pharma

Managing Director of DDReg chosen as finalist for CPhI Pharma Awards 2024

Managing director of DDReg chosen as finalist for CPHl Milan Pharma Awards 2024 under category "Woman of the Year".

Sep 25, 2024

DDReg Opens Entity in Singapore

DDReg Pharma

DDReg Opens Entity in Singapore

DDReg is thrilled to announce the establishment of its new office in Singapore. Reach out to DDReg for local support in ASEAN markets.

Apr 9, 2024